Background: An escalation in cases of rhinomaxillary mucormycosis among post-COVID patients is being reported. However, there is limited information about periodontal features in mucormycosis cases. This study explored the periodontal signs and symptoms among post-COVID mucormycosis individuals.
Materials And Methods: This cross-sectional study was carried out with a total of 25 post-COVID mucormycosis patients attending tertiary care public teaching hospital. Clinical and radiographic assessments were done.
Results: An elevation in mean probing pocket depth (PPD) up to 6.21 ± 2.7 mm was noted. Nearly 16%-40% of patients had Miller's Grade III mobility in the affected site. Forty-four per cent had localized single or multiple abscess, 40% had palatal swelling, 32% had necrosis of soft tissue and bone exposure, and 52% had maxillary dentoalveolar segmental mobility in the affected site. Radiographic examination revealed varying stages of interdental bone loss.
Conclusion: The present study observed an increase in mobility and mean PPD which did not commiserate with interdental bone loss in the affected maxillary region.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431227 | PMC |
| http://dx.doi.org/10.4103/jisp.jisp_429_22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of myeloid-derived suppressor and Th17/Treg cells in post-COVID-19 Rhino-Orbital mucormycosis cases.
Immunopharmacol Immunotoxicol
February 2025
College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
Rhino-Orbital-Cerebral Mucormycosis (ROCM) cases increased sharply in India during the second COVID-19 wave. Due to uncontrolled hyperglycemia, prolonged steroid use, and high ferritin levels, the immune system was dysregulated throughout this surge. Our study examined post-COVID-19 ROCM patients' T regulatory cell (Treg), T helper 17 cell (Th17) and Myeloid derived suppressor cell (MDSC) levels before and after three months of treatment.
View Article and Find Full Text PDFGuillain-Barre Syndrome in a Post-COVID-19 Patient who had Rhino-Orbital Mucormycosis.
Neurol India
November 2024
Department of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, Uttar Pradesh, India.
Comprehensive Management of Rhino-Orbito-Cerebral Mucormycosis Post-COVID-19: A Case Report.
Clin Case Rep
December 2024
Trauma Research Center Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences Shiraz Iran.
Post-COVID-19 mucormycosis, particularly the rhino-orbital-cerebral form, can be life-threatening. This case highlights the importance of maintaining high clinical suspicion, especially in patients with recent COVID-19 history. Prompt diagnosis, aggressive surgical debridement, and antifungal therapy are crucial for successful management, even in patients without traditional risk factors.
View Article and Find Full Text PDFA Case of Post-COVID Mucormycosis in a Diabetic Patient in Pakistan.
Cureus
November 2024
Ophthalmology Department, Shaikh Zayed Hospital, Lahore, PAK.
Mucormycosis is a rare but potentially fatal angioinvasive fungal infection, caused by filamentous molds of the order Mucorales, which primarily affects immunocompromised individuals and is characterized by high mortality rates. Diabetes mellitus (DM) is the most common risk factor for mucormycosis. During the COVID-19 pandemic, the number of cases significantly increased.
View Article and Find Full Text PDFPost-COVID Mucormycosis-Conceptual Etiology and New Treatment Options.
J Maxillofac Oral Surg
December 2024
Radix Clinic, Vadodara, Gujarat 390021 India.
Article Synopsis
- COVID-19, caused by SARS-CoV-2, increases the risk of opportunistic infections like mucormycosis, particularly in patients with conditions such as diabetes or those receiving immunosuppressive treatments.
- New research indicates that post-COVID mucormycosis can occur in young, non-diabetic patients, potentially linked to factors like coagulopathy and microembolism that allow fungi to invade.
- A proposed treatment strategy combines antifungal medications with fibrinolytic agents to address microcoagulopathy, leading to better recovery and healing outcomes for those affected by post-COVID mucormycosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!